AI assistant
DR REDDYS LABORATORIES LTD Regulatory Filings 2021
30528_rns_2021-02-22_76814ea0-10fe-4273-a128-1a2aa3e4cd35.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
February 22, 2021
Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Mumbai – 400 001 Mumbai – 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/ 22722037 / 22722039 26598238
Dalal Street, Fort Bandra-Kurla Complex, Bandra (East),
Scrip Code: 500124 Scrip Code: DRREDDY-EQ
Dear Sirs,
Sub: Press Release
Please find enclosed a Press Release on "Dr. Reddy's Laboratories announces the launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market."
This is for your information.
With regards,
Sandeep Poddar Company Secretary
Encl: As above
CC:- New York Stock Exchange Inc.(Stock Code :RDY) NSE IFSC Ltd
DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.
| CONTACT | |
|---|---|
| INVESTOR RELATIONS | MEDIA RELATIONS |
| AMIT AGARWAL[email protected](Ph: +91-40-49002135) | APARNA TEKURI[email protected](PH: +91-40- 49002446) |
Dr. Reddy's Laboratories announces the launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market
…..….…………………………………………………………………………………………………………………………………………………………………...
………………………………………………………………………………………………………………………..……………….
Hyderabad, India, February 22, 2021 For Immediate Release
Hyderabad, India and Princeton, NJ, USA. February 22, 2021— Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Lansoprazole DR Orally Disintegrating Tablets a therapeutic equivalent generic version of Prevacid SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Dr. Reddy's Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).
Please see the full prescribing information. https://www.drreddys.com/pi/lansoprazoledr\_odtus\_outsert\_v\_3.pdf
Prevacid® is a trademark of Takeda Pharmaceuticals U.S.A., Inc.
*IQVIA National Sales Perspective: Retail and Non-Retail MAT December 2020
RDY-0221-329
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
……………………………………………………………………………………………………………………………………………………………………..
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forwardlooking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues**,** and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."
Digitally signed by SANDEEP PODDAR DN: c=IN, o=Personal, pseudonym=5baa65b04542ac0f9e3878c9d 91f0db36d0548a0, 2.5.4.20=bfda99c592e4dc5b7a2e12970b95 05d6d51634ab609953e7b6cd73ea7af4939 4, postalCode=500084, st=TELANGANA, serialNumber=8185d5106ea0d6196f14ae6 60c09bac334f5ebc1a1790e158f29af33bf20 8cac, cn=SANDEEP PODDAR Date: 2021.02.22 10:32:31 +05'30'